BioCryst Pharmaceuticals Inc. [NASDAQ: BCRX] stock went on a downward path that fall over -0.36% on Thursday, amounting to a one-week price decrease of less than -1.24%. The company report on July 28, 2021 that BioCryst Appoints Vincent Milano to Board of Directors.
BioCryst Pharmaceuticals, Inc. (Nasdaq:BCRX) announced that the company has appointed hereditary angioedema (HAE) and rare disease industry leader, Vincent Milano, to its board of directors.
Mr. Milano currently serves as chief executive officer of Idera Pharmaceuticals, Inc., and previously served as chairman, president and chief executive officer of ViroPharma, which successfully developed and launched Cinryze for the treatment of HAE in the United States and Europe, prior to its acquisition by Shire in 2014. Prior to joining ViroPharma in 1996, he served as a senior manager at KPMG LLP, an independent registered public accounting firm.
Over the last 12 months, BCRX stock rose by 297.16%. The one-year BioCryst Pharmaceuticals Inc. stock forecast points to a potential upside of 6.32. The average equity rating for BCRX stock is currently 2.00, trading closer to a bullish pattern in the stock market.
The market cap for the stock reached $2.93 billion, with 177.34 million shares outstanding and 176.16 million shares in the current float. Compared to the average trading volume of 3.55M shares, BCRX stock reached a trading volume of 1870489 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Guru’s Opinion on BioCryst Pharmaceuticals Inc. [BCRX]:
Based on careful and fact-backed analyses by Wall Street experts, the current consensus on the target price for BCRX shares is $17.89 per share. Analysis on target price and performance of stocks is usually carefully studied by market experts, and the current Wall Street consensus on BCRX stock is a recommendation set at 2.00. This rating represents a strong Buy recommendation, on the scale from 1 to 5, where 5 would mean strong sell, 4 represents Sell, 3 is Hold, and 2 indicates Buy.
Cowen have made an estimate for BioCryst Pharmaceuticals Inc. shares, keeping their opinion on the stock as Outperform, with their previous recommendation back on March 01, 2021. While these analysts kept the previous recommendation, JP Morgan raised their target price to Overweight. The new note on the price target was released on September 29, 2020, representing the official price target for BioCryst Pharmaceuticals Inc. stock.
The Average True Range (ATR) for BioCryst Pharmaceuticals Inc. is set at 0.71, with the Price to Sales ratio for BCRX stock in the period of the last 12 months amounting to 91.50.
BCRX Stock Performance Analysis:
BioCryst Pharmaceuticals Inc. [BCRX] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -1.24. With this latest performance, BCRX shares gained by 8.20% in over the last four-week period, additionally plugging by 92.42% over the last 6 months – not to mention a rise of 297.16% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for BCRX stock in for the last two-week period is set at 56.19, with the RSI for the last a single of trading hit 56.41, and the three-weeks RSI is set at 56.48 for BioCryst Pharmaceuticals Inc. [BCRX]. The present Moving Average for the last 50 days of trading for this stock 16.02, while it was recorded at 16.98 for the last single week of trading, and 10.56 for the last 200 days.
Insight into BioCryst Pharmaceuticals Inc. Fundamentals:
Operating Margin for any stock indicates how profitable investing would be, and BioCryst Pharmaceuticals Inc. [BCRX] shares currently have an operating margin of -952.90 and a Gross Margin at +90.59. BioCryst Pharmaceuticals Inc.’s Net Margin is presently recorded at -1026.35.
Return on Total Capital for BCRX is now -131.36, given the latest momentum, and Return on Invested Capital for the company is -195.22. Return on Equity for this stock declined to -1,925.37, with Return on Assets sitting at -71.69. Additionally, BCRX Total Debt to Total Capital is recorded at 114.21, with Total Debt to Total Assets ending up at 46.24.
Reflecting on the efficiency of the workforce at the company, BioCryst Pharmaceuticals Inc. [BCRX] managed to generate an average of -$743,146 per employee. Receivables Turnover for the company is 1.16 with a Total Asset Turnover recorded at a value of 0.07.BioCryst Pharmaceuticals Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 2.70 and a Current Ratio set at 2.70.
BCRX Stock EPS
The progress of the company may be observed through the prism of EPS growth rate, while Wall Street analysts are focusing on predicting the 5-year EPS growth rate for BCRX. When it comes to the mentioned value, analysts are expecting to see the 5-year EPS growth rate for BioCryst Pharmaceuticals Inc. go to 19.90%.
BioCryst Pharmaceuticals Inc. [BCRX] Insider Position Details
There are presently around $1,800 million, or 61.20% of BCRX stock, in the hands of institutional investors. The top three institutional holders of BCRX stocks are: BLACKROCK INC. with ownership of 16,241,775, which is approximately -0.111% of the company’s market cap and around 0.40% of the total institutional ownership; BAKER BROS. ADVISORS LP, holding 12,710,818 shares of the stock with an approximate value of $213.03 million in BCRX stocks shares; and VANGUARD GROUP INC, currently with $162.57 million in BCRX stock with ownership of nearly -16.374% of the company’s market capitalization.
Positions in BioCryst Pharmaceuticals Inc. stocks held by institutional investors increased at the end of August and at the time of the August reporting period, where 100 institutional holders increased their position in BioCryst Pharmaceuticals Inc. [NASDAQ:BCRX] by around 20,778,273 shares. Additionally, 99 investors decreased positions by around 33,617,055 shares, while 21 investors held positions by with 53,018,587 shares. The mentioned changes placed institutional holdings at 107,413,915 shares, according to the latest SEC report filing. BCRX stock had 42 new institutional investments in for a total of 13,248,271 shares, while 33 institutional investors sold positions of 7,175,306 shares during the same period.